Supernus Pharmaceuticals (SUPN) Deferred Taxes (2016 - 2026)

Supernus Pharmaceuticals (SUPN) has 11 years of Deferred Taxes data on file, last reported at $5.9 million in Q1 2026.

• On a quarterly basis, Deferred Taxes rose 248.27% year-over-year to $5.9 million in Q1 2026; TTM through Mar 2026 was $15.1 million, a 181.06% increase from a year earlier, with the FY2025 full-year figure at $5.2 million, up 125.85% from the prior year.
• Deferred Taxes for Q1 2026 stood at $5.9 million, down from $19.0 million in the prior quarter.
• Over the last five years, Deferred Taxes for SUPN reached as high as $19.0 million in Q4 2025 and fell as low as -$13.0 million in Q1 2022.
• Historically, Deferred Taxes has averaged -$3.6 million across 5 years, with a median of -$5.5 million in 2024.
• Across the five-year window, Deferred Taxes tumbled 1160.23% in 2024 and jumped 26493.06% in 2025, its largest moves.
• Year by year, Deferred Taxes stood at -$7.8 million in 2022, then slumped by 34.78% to -$10.5 million in 2023, then jumped by 99.31% to -$72000.0 in 2024, then soared by 26493.06% to $19.0 million in 2025, then tumbled by 68.87% to $5.9 million in 2026.
• Per Business Quant data, the three most recent Deferred Taxes figures were $5.9 million in Q1 2026, $19.0 million in Q4 2025, and -$2.6 million in Q3 2025.